TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05264792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Support
Description: This support package will include:~1. one-on-one remote (phone/web-based) technical assistance sessions (every two weeks) between the facility team and the study team Implementation Support Coaches. These sessions will involve a discussion on successes and challenges in integrating depression screening with routine care and developing strategies to improve screening, using the PDSA (Plan Do Study Act) cycle model.~2. remote peer learning community (peers include ANMs and Nurses who administer screening) through a cross-facility WhatsApp group moderated by the study team Coaching Support Team.~3. virtual peer learning network conferences (quarterly) moderated by the Coaching Support Team focused on lessons learned in improving depression screening.~The 9-month intervention duration is informed by the Institute of Healthcare Improvement's Breakthrough Series guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Implementation Support
Description: This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Implementation Support
Description: This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.
Study: NCT06418477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-CyBorD
Description: Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis.
Study: NCT06649409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: vamorolone 20 mg/kg single dose on Day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone 200 mg single dose on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone
Description: Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.

Intervention type: DRUG
Group type: OTHER
Intervention: Fludrocortisone
Description: Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.
Study: NCT06590389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mandala activity
Description: A descriptive patient form, VAS and STAI-I were applied before surgery. After the surgery, VAS and STAI-I were applied before and after the mandala activity until the patient was discharged. The VAS form was applied every 4 hours until the patient was discharged. This process was repeated in the same way for the entire intervention group.
Study: NCT06590025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INtegral Cognitive REMediation program
Description: This comprehensive functional remediation program includes a traditional CR component with a specialized therapist (based on the compensation model) and a CCT component adapted to the difficulties of each patient. The inclusion of both aspects allows adapting the intervention to the present difficulties by forming new strategies with compensation techniques and promoting translation to everyday life. Therefore, the intervention aims at improving cognitive functioning (beyond a mere training) so as to facilitate the improvement and maintenance of psychosocial functioning for patients with MDD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for depression
Description: Psycho-education refers to educating individuals about depression and the various treatment options. It is a form of therapy that aims to provide individuals with the knowledge and skills to manage their mental health symptoms effectively.
Study: NCT05838339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Sleep Intervention
Description: The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Sleep Intervention
Description: The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.
Study: NCT06252701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of Ultra-processed foods
Description: Reduction of Ultra-processed foods for four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of Ultra-processed foods
Description: Reduction of Ultra-processed foods for four weeks.
Study: NCT06667037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses
Description: Ortho-k lenses will be administered nightly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ortho-k lenses
Description: Ortho-k lenses will be administered nightly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% Atropine
Description: 0.01% Atropine will be administrated twice a day with an interval of about 12 hours. Drop into the conjunctival sac and immediately compress the lacrimal sac of the inner canthus for 2-3 minutes.
Study: NCT05398185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleverCap
Description: The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
Study: NCT06612099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Individuals in this group will perform aerobic exercise training on a treadmill/bicycle under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 training sessions. Moderate intensity aerobic exercise training will be set by calculating the target heart rate range. During the training session, individuals will receive a total of 50 minutes of training, consisting of a 10-minute warm-up, 30 minutes of moderate walking/cycling and a 10-minute cool-down period. In addition to the aerobic exercise training group, on the days he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, with weights of 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mat Pilates Exercise
Description: Individuals in this group will perform mat pilates exercises under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 exercise sessions. During the exercise sessions, individuals will undergo a 50-minute mat pilates exercise program. In addition to the mat pilates exercise group, on the days when he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
Study: NCT06667869

Intervention type: DRUG
Intervention: Sedative
Description: Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.

Intervention type: DRUG
Intervention: Sedative
Description: Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.
Study: NCT06621043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTI164
Description: Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.
Study: NCT06617910

Intervention type: RADIATION
Intervention: SBRT by Cyberknife
Description: The patients with sinonasal maliganacy receive curative surgery then receive adjuvant RT by the method of SBRT by Cyberknife.
Study: NCT06621381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentrated exposure and response prevention
Description: The intervention consists of: Psychoducation for the patients (1 session, 2-3h in group format), psychoeducation for the legal guardians (1 session, 3h in group format), exposure and response prevention (3-4 sessions, 9-12h over the course of one week, individual format), group reunions for sharing experiences, motivational work and relapse prevention ( 2 sessions, 3h)
Study: NCT06618495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)
Description: Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 4 weeks.
Study: NCT06619106

Intervention type: OTHER
Intervention: Cognitive test
Description: Cognitive test based on building blocks
Study: NCT06618937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment medication withdrawal strategy
Description: The study aims to compare early biomarkers-guided versus conventional unguided drugs withdrawal strategy.
Study: NCT06621433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-PRF with CAF
Description: Blood sample will be obtained from the patient, conveyed into a titanium tube and immediately centrifuged at 2700 rpm for 12 mins at room temperature using fixed angle centrifuge (PRF Process, Tangkula800-1, China). The fibrin clot will be collected and placed in the PRF compression device (PRF GRF box) and condensed to produce a uniform T-PRF membrane which will be inserted over the recession area and covered by the coronally advanced flap.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SECTG with CAF
Description: Sub epithelial connective tissue graft will be obtained from the donor site (hard palate), placed into recipient site and secured by sutures, then covered by a coronally advanced flap.
Study: NCT06618508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual debridement
Description: Traditional technique which consists of scraping off the irregular epithelium to allow a new layer to form.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy
Description: New technique which has been increasingly used and which consists of a 193nm excimer laser that breaks molecular bonds between cells on the epithelial surface.
Study: NCT06620991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine
Description: A loading dose of 1-5 mg IV bolus over 1 minute is given followed by an IV infusion of a rate of 0.1-2 mg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over a volume of 10ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: A loading dose of 1 mg/kg IV infused over 1 minute is given followed by an IV infusion of 0.15-0.3 mg/kg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over total volume of 10ml
Study: NCT06620718

Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronectomy
Description: The inferior alveolar nerve and buccal nerve were blocked with maxicaine anaesthetic solution (articaine hydrochloride 40 mg, epinephrine hydrochloride 0.006 mg). Incisions were applied uniformly across all patients, and a triangular flap technique was employed. After elevating the flap and exposing the bone, the bone overlying the crown of the tooth was removed using a bone round bur to fully visualize the tooth\&#39;s crown. Once the crown was fully exposed, the crown preparation was initiated at the enamel-dentin junction using a fissure bur. The crown preparation was completed without leaving any sharp edges, and the crown was extracted. Then, the exposed pulp was washed with sterile serum without any further intervention. The surgical area was sutured using 5/0 silk. Analgesic (25 mg of dexketoprofen trometamol twice a day) and antibiotic (125 mg clavulanic acid, 875 mg amoxicilin twice a day) drugs were described.
Study: NCT06619353

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: Patients' blood samples are tested at 1 month, and then annually for 3 years post-intervention to assess residual thrombotic, metabolic, and inflammatory risk.

Intervention type: OTHER
Intervention: DICOM Dataset
Description: Patients' DICOM dataset is evaluated using artificial intelligence-based quantitative coronary analysis to assess a procedural risk.
Study: NCT06622993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The experimental group will receive the SKILLS program, i.e. 10 group psychotherapy sessions.
Study: NCT06621303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diabetic foot ulcer treatment
Description: The trial is designed to last up to 26 weeks, including a screening period of 1 week, a treatment period of 1 week, and an observation period of 24 weeks. According to the inclusion criteria, 10 diabetic patients with ulcers will be clinically screened, and after signing the informed consent form, they will be assigned a number. Post-injection of OPM cells, wound assessments are conducted weekly, with physical examinations and vital signs (pulse, blood pressure) recorded at weeks 4, 8, 12, 16, 20, and 24. Clinical laboratory tests (routine blood tests, tumor markers, etc.) are performed at week 12. Vascular CTA and immune cell count in wound lavage fluid are conducted at week 24 post-cellular intervention, followed by a final examination at week 24.
Study: NCT06620003

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cAd3-Marburg vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution for injection.
Study: NCT06621550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Participants will receive a single session of HIIT, which last for 19 minutes in duration. During the HIIT session, participants will complete 2 minutes stretching warm-up exercise, followed by a video of exercises which will be projected on the screen to facilitate the participants to follow. The exercise in the video involves various combinations of aerobic and core resistance exercise such as squat jump, jump lunge, push up, burpee, mountain climber etc. The exercise involved bodyweight or minimal basic equipment only, the workout to rest ratio is 45 secs: 15 secs. Participants' heart rate will be kept surveillance and to maintain their respective heart rate attained 85% of aged predicted maximal heart rate during the workout period.
Study: NCT06622421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery
Description: Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional surgery
Description: Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
Study: NCT06622915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Doppler imaging and Conventional Echocardiography
Description: non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Doppler imaging and Conventional Echocardiography
Description: non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum
Study: NCT05989711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemvidutide
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemvidutide
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT06618768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of an aronia-mixture to prevent Urinary Tract Infections in female patients
Description: The present pilot study will assess the feasibility of methods and procedures to be used in a larger study and contribute to establish power calculations required to conduct a randomised clinical trial which will examine whether consumption of 1 dL aronia-mixture/day for six months will reduce prevalence of symptomativ UTi episodes among adult women with a recent history of uncomplicated, recurrent UTIs.
Study: NCT05248113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of cochlear nerve
Description: Intraoperative electrical stimulation of the cochlear nerve in patients undergoing surgery for resection of vestibular schwannoma. Activation of the auditory system monitored with scalp recording of auditory brainstem response.
Study: NCT06665880

Intervention type: OTHER
Intervention: Routine clinical treatment
Description: Routine clinical treatment is based on the latest international guidelines for DRE.

Intervention type: OTHER
Intervention: Routine clinical treatment
Description: Routine clinical treatment is based on the latest international guidelines for DRE.
Study: NCT06620276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 8 sessions of one hour of Acceptance and Commitment Therapy delivered one on one by a licensed psychologist with experience and training in this intervention.